Presentation is loading. Please wait.

Presentation is loading. Please wait.

Growth factor PI3K PDK1/2 PIP 3 AKT CASP9 FOXO1 BAD CDKN1A CDKN1B MDM2 GSK3B CHUK mTOR PTEN miR-26ab/1297; miR-148/152; miR-103/107; miR-19; miR-425/489;

Published byAugustus Small Modified over 8 years ago

Similar presentations

Presentation on theme: "Growth factor PI3K PDK1/2 PIP 3 AKT CASP9 FOXO1 BAD CDKN1A CDKN1B MDM2 GSK3B CHUK mTOR PTEN miR-26ab/1297; miR-148/152; miR-103/107; miR-19; miR-425/489;"— Presentation transcript:

1 Growth factor PI3K PDK1/2 PIP 3 AKT CASP9 FOXO1 BAD CDKN1A CDKN1B MDM2 GSK3B CHUK mTOR PTEN miR-26ab/1297; miR-148/152; miR-103/107; miR-19; miR-425/489; miR-29abc; miR-130/301; miR- 25/32/92/92ab/363/367; miR-23ab; miR-141/200a; miR- 338/338-3p; miR-132/212; miR-22; miR-144; miR-17- 5p/20/93.mr/106/519.d; miR-205; miR-139-5p; miR-181; miR-200bc/429; miR-365; miR-216/216a; miR-214/761; miR-10; miR-153; miR-193ab; miR-183; miR-106/302; miR-194; miR-490/490-3p; miR-217; miR-129/129-5p miR-21 miR-203; miR-106/302; miR-10; miR-148/152; miR- 155; miR-19; miR-124/506; miR-132/212; miR- 124/506; miR-122; miR-203; miR-143; miR-142-3p; miR-25/32/92/92ab/363/367; miR-33/33ab; miR- 129/129-5p; miR-24 miR-130/301; miR-96/1271; miR-128; miR-138; miR-216/216a; miR- 139-5p; miR-148/152; miR-155; miR-143; miR-27ab; miR-137; miR- 181; miR-150; miR-425/489; miR-7/7ab; miR-129/129-5p; miR-22; miR-140/140-5p/876-3p; miR-187; miR-216/216b; miR-9; miR-182; miR-125/351; miR-205; miR-375; miR-25/32/92/92ab/363/367; miR- 33/33ab; miR-19; miR-133; miR-23ab; miR-24 miR-214/761; miR-490/490-3p; miR- 218; miR-125/351; miR-24; miR-31; miR-128; miR-124/506; miR-141/200a miR-106/302; miR-138; miR- 183; miR-338/338-3p; miR- 143; miR-22 miR-144; miR-96/1271; miR-7/7ab; miR-99ab/100; miR-135; miR-101; miR-375; miR-128; miR-103/107 miR-26ab/1297; miR-199/199-5p miR-221/222; miR-26ab/1297; miR- 208/208ab; miR-499/499-5p; miR-10; miR- 194; miR-24 miR-23ab; miR-148/152; miR-15/16/195/424/497; let-7/98; miR-208/208ab; miR-499/499-5p; miR- 223; miR-21/590-5p; miR-133; miR-130/301; miR-425/489 miR-221/222; miR-150; miR-24; miR- 200bc/429; miR-196ab; miR-190; miR-218; miR-199/199-5p; miR-148/152; miR-181; miR- 194; miR-155; miR-34a/34b-5p/34c/34c- 5p/449/449abc/699; miR-141/200a; miR-153; miR-455/455-5p; miR-122; miR-223; miR- 129/129-5p miR-17-5p/20/93.mr/106/519.d; miR-365; let- 7/98; miR-130/301; miR-208/208ab; miR- 499/499-5p; miR-132/212; miR-22; miR-101; miR-124/506; miR-148/152; miR-199/199- 5p; miR-15/16/195/424/497; miR-141/200a; miR-145 miR-106 miR-223; miR-96/1271; miR-135; miR-101; miR- 128; miR-27ab; miR-21/590-5p; miR-183; miR- 132/212; miR-26ab/1297; miR-145; miR- 216/216a; miR-15/16/195/424/497; miR-196ab; miR-129/129-5p; miR-144; miR-143; miR-182; miR-200bc/429; miR-338/338-3p; miR-142-3p; miR-204/211; miR-194; miR-139-5p; miR- 490/490-3p; miR-9; miR-216/216b; miR-221/222; miR-153; miR-133; miR-218; miR-365 miR-153; miR-129/129-5p; miR-490/490-3p; miR-34a/34b-5p/34c/34c-5p/449/449abc/699 miR-182; miR-96/1271; miR-155; miR-146; miR- 130/301; miR-193ab; miR-7/7ab; miR-10; miR- 140/140-5p/876-3p; miR-124/506; miR-223 NOS3 miR-31; miR-155; miR-124/506; miR- 34a/34b-5p/34c/34c-5p/449/449abc/699 PDE3A: miR-128; miR-139-5p; miR-138; miR- 216/216b; miR-27ab; miR-21/590-5p; miR-155; miR-204/211; miR-218; miR-210 PDE3B: miR-205; miR-33/33ab; miR- 15/16/195/424/497; miR-103/107; miR-17- 5p/20/93.mr/106/519.d; miR-27ab; miR-181; miR- 9; miR-144; miR-153; miR-214/761; miR-223; miR-425/489; miR-499/499-5p; miR- 25/32/92/92ab/363/367; miR-141/200a; miR-128 PDE3 A/B GFR (e.g. ERBB2) Supplemental Figure 1. Overview of Akt signaling. Summary of Akt signaling and predicted miRNA interactions. miRNAs that were described to be downregulated in prostate cancer are highlighted in green, while upregulated miRNAs are highlighted in red; all other potential interactions are highlighted in black. Target interactions were predicted with TargetScan 5.1. miRNAs presented in this figure are all highly conserved among vertebrates; for a list of other miRNAs see Supplemental Table 1.

Download ppt "Growth factor PI3K PDK1/2 PIP 3 AKT CASP9 FOXO1 BAD CDKN1A CDKN1B MDM2 GSK3B CHUK mTOR PTEN miR-26ab/1297; miR-148/152; miR-103/107; miR-19; miR-425/489;"

Similar presentations

Supplemental Figure 1 A No. at risk T3 530 483 304 185 50 T2 559 545 373 228 76 T1 540 532 375 208 64.

Supplemental Figure 1 A No. at risk T T T
P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.
Supplimental figure 1. Melanoma free survival curve (A) and summary table (B) for median survival and melanoma free survival for each genotype. All of.

Supplimental figure 1. Melanoma free survival curve (A) and summary table (B) for median survival and melanoma free survival for each genotype. All of.
Targeting the IGF Pathway in Pediatric Sarcomas-Lessons Learned and Questions Raised Lee J. Helman, M.D. Scientific Director for Clinical Research,Center.

Targeting the IGF Pathway in Pediatric Sarcomas-Lessons Learned and Questions Raised Lee J. Helman, M.D. Scientific Director for Clinical Research,Center.
Not division…But growth. Cells must grow PI3K GFR Akt Rheb Ras mTOR Tuberin/ Hamartin PTEN Neurofibromin Tuberous sclerosis complex Neurofibromatosis.

Not division…But growth. Cells must grow PI3K GFR Akt Rheb Ras mTOR Tuberin/ Hamartin PTEN Neurofibromin Tuberous sclerosis complex Neurofibromatosis.
MiR-19b/20a/92a regulates the self- renewal and proliferation of gastric cancer stem cells Journal of Cell Science (IF=5.325) 报告人：黄美玲 2014-11-27.

MiR-19b/20a/92a regulates the self- renewal and proliferation of gastric cancer stem cells Journal of Cell Science (IF=5.325) 报告人：黄美玲
MicroRNA implication in urinary bladder cancer A. Zaravinos 1, J. Radojicic 3, G.I. Lambrou 2, D. Volanis 1,4, D. Delakas 4, E.N. Stathopoulos 3, D.A.

MicroRNA implication in urinary bladder cancer A. Zaravinos 1, J. Radojicic 3, G.I. Lambrou 2, D. Volanis 1,4, D. Delakas 4, E.N. Stathopoulos 3, D.A.
Supplemental Data Fig. 1A. Standard curves of miR-34c-5p using synthetic miRNAs.

Supplemental Data Fig. 1A. Standard curves of miR-34c-5p using synthetic miRNAs.
Supplemental Fig. 1A. Standard curve of miR-30a-5p using synthetic miRNA.

Supplemental Fig. 1A. Standard curve of miR-30a-5p using synthetic miRNA.
Apostolos Zaravinos and Constantinos C Deltas Molecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, Department of Biological.

Apostolos Zaravinos and Constantinos C Deltas Molecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, Department of Biological.
OncomiR and tumor-suppressor miR expression in triple-negative primary breast cancer. Jelena Radojicic 1, Apostolos Zaravinos 2, Thomas Vrekoussis 1, Maria.

OncomiR and tumor-suppressor miR expression in triple-negative primary breast cancer. Jelena Radojicic 1, Apostolos Zaravinos 2, Thomas Vrekoussis 1, Maria.
MiR-21 can be used as independent prognostic factor for survival and metastasis in urinary bladder cancer. Apostolos Zaravinos 1, Jelena Radojicic 3, George.

MiR-21 can be used as independent prognostic factor for survival and metastasis in urinary bladder cancer. Apostolos Zaravinos 1, Jelena Radojicic 3, George.
Affymetrix 2.0 miRNA arrays on lung tissue RNA n=3-4 mice/strain 92 differentially expressed miRNAs 38 miRNAs both differentially and highly expressed.

Affymetrix 2.0 miRNA arrays on lung tissue RNA n=3-4 mice/strain 92 differentially expressed miRNAs 38 miRNAs both differentially and highly expressed.
How to present a scientific paper Dr. Rebecca B. Riggins Department of Oncology, Georgetown University

How to present a scientific paper Dr. Rebecca B. Riggins Department of Oncology, Georgetown University
Partial recovery Lost sample 1,000 fmols 0.1 fmols 1.0 fmols Neg. control Supplemental Fig. 1. Quality control for extraction procedures using spiked-in.

Partial recovery Lost sample 1,000 fmols 0.1 fmols 1.0 fmols Neg. control Supplemental Fig. 1. Quality control for extraction procedures using spiked-in.
Supplemental Table 1. Oligonucleotide sequences used for mRNA expression analysis by qPCR. Primer name Forward Primer 5’- 3’Reverse Primer 5’-3’ KLK3 5’-GTGCTTGTGGCCTCTCG-3’

Supplemental Table 1. Oligonucleotide sequences used for mRNA expression analysis by qPCR. Primer name Forward Primer 5’- 3’Reverse Primer 5’-3’ KLK3 5’-GTGCTTGTGGCCTCTCG-3’
MicroRNAs as Biomarkers for Acute Graft Versus Host Disease Prediction

MicroRNAs as Biomarkers for Acute Graft Versus Host Disease Prediction
Expression profile of oncomiRs and tumor-suppressor miRs in urothelial carcinoma of the bladder Apostolos Zaravinos 1, George I. Lambrou 2, Jelena Radojicic.

Expression profile of oncomiRs and tumor-suppressor miRs in urothelial carcinoma of the bladder Apostolos Zaravinos 1, George I. Lambrou 2, Jelena Radojicic.
Figure S1 cmSP165/166 severe b MIM159 (mir159a) a Figure S1: Detailed phenotype of severe cmSP165/166 and MIM159 plants. Severe cmSP165/166 (15x) plants.

Figure S1 cmSP165/166 severe b MIM159 (mir159a) a Figure S1: Detailed phenotype of severe cmSP165/166 and MIM159 plants. Severe cmSP165/166 (15x) plants.
2014.11.27 Yuna Jo. Introduction Prostate cancer (PCa) continues to burden the Western world with its high rates of incidence and mortality despite the.

Yuna Jo. Introduction Prostate cancer (PCa) continues to burden the Western world with its high rates of incidence and mortality despite the.

Similar presentations

Ads by Google